Search

Your search keyword '"Sagnelli, E"' showing total 976 results
Start Over Author "Sagnelli, E"
976 results on '"Sagnelli, E"'

7. Impact of DAA-Based Regimens on HCV-Related Extra-Hepatic Damage: A Narrative Review

Author

Sagnelli E, Sagnelli C, Russo A, Pisaturo M, Camaioni C, Astorri R, Coppola N, Sagnelli, E., Sagnelli, C., Russo, A., Pisaturo, M., Camaioni, C., Astorri, R., Coppola, N., Sagnelli, E, Sagnelli, C, Russo, A, Pisaturo, M, Camaioni, C, Astorri, R, and Coppola, N

Subjects
Antiviral Agent, Hepaciviru, HCV extrahepatic manifestation, virus diseases, Interferon-free DAA regimen, Hepacivirus, Hepatitis C, Chronic, Antiviral Agents, Hepatitis C, digestive system diseases, Cryoglobulinemia, Humans, Hepatitis C viru, Human
Abstract

Two-third of patients with chronic hepatitis C show extrahepatic manifestations due to HCV infection of B lymphocytes, such as mixed cryoglobulinemia and non-Hodgkin B-cell lymphoma, or develop a chronic inflammatory status that may favor the development of adverse cardiovascular events, kidney diseases or metabolic abnormalities. DAAs treatments induce HCV eradication in 95% of treated patients, which also improves the clinical course of extrahepatic manifestations, but with some limitations. After HCV eradication a good compensation of T2DM has been observed, but doubts persist about the possibility of obtaining a stable reduction in fasting glucose and HbA1c levels. Chronic HCV infection is associated with low total and LDL cholesterol serum levels, which however increase significantly after HCV elimination, possibly due to the disruption of HCV/lipid metabolism interaction. Despite this adverse effect, HCV eradication exerts a favorable action on cardiovascular system, possibly by eliminating numerous other harmful effects exerted by HCV on this system. DAA treatment is also indicated for the treatment of patients with mixed cryoglobulinemia syndrome, since HCV eradication results in symptom reduction and, in particular, is effective in cryoglobulinemic vasculitis. Furthermore, HCV eradication exerts a favorable action on HCV-related lymphoproliferative disorders, with frequent remission or reduction of clinical manifestations. There is also evidence that HCV clearance may improve impaired renal functions, but same conflicting data persist on the effect of some DAAs on eGFR.

Published
2020

12. Effect of prednisone priming followed by alfa-interferon in treatment of children with chronic hepatitis B: an interim analysis of a controlled trial

Author

Utili, Riccardo, Sagnelli, E., Giusti, G., Ruggiero, G., Piccinino, F., Galanti, B., Adinolfi, L. E., Aprea, L., Cesaro, G., Digilio, L., Felaco, F. M., Filippini, P., Gaeta, G. B., Marrone, A., Nardiello, S., Pasquale, G., Pizzella, T., Russo, M., Santarpia, L., Sardaro, C., D’Amora, T., De Bac, C., editor, Taliani, G., editor, and Gerlich, W. H., editor

Published
1992
Full Text
View/download PDF

13. Italian consensus recommendations for the management of hepatitis C infection in patients with rheumatoid arthritis

Author

Sebastiani, M, Milazzo, L, Atzeni, F, Vacchi, C, Manfredi, A, Quartuccio, L, Scire, C, Gaeta, G, Lapadula, G, Armignacco, O, Tavio, M, D'Angelo, S, Meroni, P, Bazzichi, L, Grassi, W, Mathieu, A, Mastroianni, C, Sagnelli, E, Santantonio, T, Foppa, C, Puoti, M, Sarmati, L, Airo, P, Epis, O, Scrivo, R, Gargiulo, M, Riva, A, Ciancio, G, Zehender, G, Taliani, G, Meroni, L, Sollima, S, Sarzi-Puttini, P, Galli, M, Sebastiani M., Milazzo L., Atzeni F., Vacchi C., Manfredi A., Quartuccio L., Scire C., Gaeta G. B., Lapadula G., Armignacco O., Tavio M., D'Angelo S., Meroni P., Bazzichi L., Grassi W., Mathieu A., Mastroianni C., Sagnelli E., Santantonio T., Foppa C. U., Puoti M., Sarmati L., Airo P., Epis O. M., Scrivo R., Gargiulo M., Riva A., Ciancio G., Zehender G., Taliani G., Meroni L., Sollima S., Sarzi-Puttini P., Galli M., Sebastiani, M, Milazzo, L, Atzeni, F, Vacchi, C, Manfredi, A, Quartuccio, L, Scire, C, Gaeta, G, Lapadula, G, Armignacco, O, Tavio, M, D'Angelo, S, Meroni, P, Bazzichi, L, Grassi, W, Mathieu, A, Mastroianni, C, Sagnelli, E, Santantonio, T, Foppa, C, Puoti, M, Sarmati, L, Airo, P, Epis, O, Scrivo, R, Gargiulo, M, Riva, A, Ciancio, G, Zehender, G, Taliani, G, Meroni, L, Sollima, S, Sarzi-Puttini, P, Galli, M, Sebastiani M., Milazzo L., Atzeni F., Vacchi C., Manfredi A., Quartuccio L., Scire C., Gaeta G. B., Lapadula G., Armignacco O., Tavio M., D'Angelo S., Meroni P., Bazzichi L., Grassi W., Mathieu A., Mastroianni C., Sagnelli E., Santantonio T., Foppa C. U., Puoti M., Sarmati L., Airo P., Epis O. M., Scrivo R., Gargiulo M., Riva A., Ciancio G., Zehender G., Taliani G., Meroni L., Sollima S., Sarzi-Puttini P., and Galli M.

Abstract

Objectives: The recent introduction of direct-acting antiviral agents (DAAs) which can eliminate Hepatitis C virus (HCV) had revolutionized the treatment of HCV infections also in a complex clinical setting such as the patients with rheumatoid arthritis (RA). HCV elimination is also opportune due to the availability of more efficient immunosuppressive drugs, whose effect on the course of HCV infection is largely unknown. Methods: Consensus process was endorsed by the Italian Society of Rheumatology (SIR) and the Italian Society of Infectious and Tropical Diseases (SIMIT) to review the available evidence and produce practical, hospital-wide recommendations. The consensus panel consisted of 18 infectious diseases consultants, 20 rheumatologists and one clinical epidemiologist, who used the criteria of the Oxford Centre for Evidence-based Medicine to assess the quality of the evidence and the strength of their recommendations. Results: A core-set of statements about management of patients with RA and infection by HCV have been developed to help clinicians in their clinical practice. Conclusions: A screening for HCV should be performed in all RA patients and it is mandatory before starting an immunosuppressive therapy. Finally, a DAA treatment should be considered in all HCV-infected patients.Significance and Innovations HCV antibodies should be investigated at the time of diagnosis of RA and, in any case, before starting immunosuppressive therapy with disease-modifying antirheumatic drugs (DMARDs). HCV eradication with DAA should be attempted as soon as possible, depending on patient conditions allowing a continuous oral treatment lasting 8–12 weeks Conventional and biological DMARDs are allowed in patients with HCV infection, but they should be used cautiously in presence of advanced liver disease.

Published
2019

14. Chronic hepatitis B virus infection in Italy during the twenty-first century: an updated survey in 2019

Author

Stroffolini T., Ciancio A., Furlan C., Vinci M., Niro G. A., Russello M., Colloredo G., Morisco F., Coppola N., Babudieri S., Ferrigno L., Sagnelli C., Sagnelli E., Verzon G., Latanza A., Picciotto V., Fontana R., Benigno R. G., Pontillo G., Messina V., Fiore V., Stroffolini, T., Ciancio, A., Furlan, C., Vinci, M., Niro, G. A., Russello, M., Colloredo, G., Morisco, F., Coppola, N., Babudieri, S., Ferrigno, L., Sagnelli, C., Sagnelli, E., Verzon, G., Latanza, A., Picciotto, V., Fontana, R., Benigno, R. G., Pontillo, G., Messina, V., and Fiore, V.

Subjects
0301 basic medicine, Microbiology (medical), Adult, Male, HBsAg carriers, medicine.medical_specialty, Hepatitis B virus, Cirrhosis, Antiviral treatment, HBV endemicity, HBV infection, HBV vaccination programs, 030106 microbiology, Disease, Antiviral Agents, Virus, 03 medical and health sciences, Liver disease, 0302 clinical medicine, Medical microbiology, Hepatitis B, Chronic, Internal medicine, medicine, Humans, 030212 general & internal medicine, Prospective Studies, Aged, Hepatitis, Transients and Migrants, Hepatitis B Surface Antigens, business.industry, Incidence, General Medicine, Middle Aged, medicine.disease, HBsAg carrier, Infectious Diseases, Italy, Carrier State, Hbsag carrier, Female, business, Sex ratio
Abstract

The aim of this study is to provide updates on the characteristics of chronic HBsAg carriers in Italy before the advent of new drugs eliminating or functionally inactivating the genome HBV reservoirs. HBV endemicity has greatly decreased in Italy over the past decades. A not negligible number of chronic HBsAg carriers are still alive in the country. Chronic HBsAg carriers consecutively referring to 9units in Italy were prospectively enrolled for a 6-month period in 2019. Multiple logistic regression analysis was performed to identify independent predictors of treatment. A total of 894 cases was recruited (sex ratio 1.6; mean age 53.7 ± 13.5years). The proportion of subjects born abroad was 19.0%; only 1% of cases reported current heavy alcohol intake (> 4 units/day). Chronic HBV infection, chronic HBV hepatitis, and subjects with liver cirrhosis and/or HCC represented 24.8%, 55%, and 19.3% of cases, respectively. After exclusion of the 222 subjects with chronic HBV infection, the proportion of subjects under therapy was as high as 89.3%. A more severe liver disease (OR 2.52; 95% CI = 1.25–5.14) resulted an independent predictor of the likelihood of treatment; male sex was marginally associated (OR 1.67; 95% CI = 1.02–2.76) to the chance of treatment. People born abroad had same chance than Italians native to be treated (OR 2.12; 95% CI = 0.9–4.97). The high proportion of subjects under treatment and the absence of gender and ethnic barrier against treatment sound good news. These updated figures may represent reference data for evaluating the potential impact of forthcoming new therapy against HBV-related disease.

Published
2020

18. Erratum: Characteristics of patients with hepatitis C virus-related chronic liver diseases just before the era of oral direct-acting antiviral therapy in Italy (European Journal of Gastroenterology and Hepatology (2018) 30 (676-681) DOI: 10.1097/MEG.0000000000001099)

Author

Sagnelli E., Stroffolini T., Sagnelli C., Cacopardo B., Andriulli A., Babudieri S., Coppola N., Gaeta G. B., Almasio P. L., Sagnelli E., Stroffolini T., Sagnelli C., Cacopardo B., Andriulli A., Babudieri S., Coppola N., Gaeta G.B., and Almasio P.L.

Subjects
epidemiology, liver disease
Abstract

The authors' affiliations of this article published in last year's years June issue [1] were incorrect and the should be as listed below: Evangelista Sagnellia, Tommaso Stroffolinib, Caterina Sagnellia, Bruno Cacopardoc, Angelo Andriullid, Sergio Babudierie, Nicola Coppolaa, Giovanni B. Gaetaf, Piero L. Almasiog aDepartment of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Naples, Italy bDepartment of Tropical and Infectious Diseases, Policlinico Umberto Primo, Rome, cInfectious Diseases, University of Catania, Catania, Italy dGastroenterology Unit, Fondazione 'Casa Sollievo della Sofferenza' IRCCS Hospital, San Giovanni Rotondo, Foggia, Italy eClinic of Infectious Diseases, University of Sassari, Sassari, Italy fInfectious Diseases and Viral Hepatitis Unit, Department of Internal and Specialistic Medicine, University of Campania Luigi Vanvitelli, Naples, Italy gGastroenterology and Hepatology Unit, Di.Bi.MI.S. University of Palermo, Palermo, Italy The authors apologise for this.

Published
2019

19. Erratum: Eradication of HCV infection with the direct-acting antiviral therapy in renal allograft recipients (BioMed Research International (2019) 2019 (8) DOI: 10.1155/2019/4674560)

Author

Calogero A., Sagnelli E., Creta M., Angeletti S., Peluso G., Incollingo P., Candida M., Minieri G., Carlomagno N., Dodaro C. A., CICCOZZI, ANTONELLO, Sagnelli C., Calogero, A., Sagnelli, E., Creta, M., Angeletti, S., Peluso, G., Incollingo, P., Candida, M., Minieri, G., Carlomagno, N., Dodaro, C. A., Ciccozzi, Antonello, and Sagnelli, C.

Abstract

[This corrects the article DOI: 10.1155/2019/4674560.].

Published
2019

20. Correction

Author

Sebastiani, M, Milazzo, L, Atzeni, F, Vacchi, C, Manfredi, A, Quartuccio, L, Scire, C, Gaeta, GB, Lapadula, G, Armignacco, O, Tavio, M, D'Angelo, S, Meroni, P, Bazzichi, L, Grassi, W, Mathieu, A, Mastroianni, C, Sagnelli, E, Santantonio, T, Uberti Foppa, C, Puoti, M, Sarmati, L, Airo, P, Epis, OM, Scrivo, R, Gargiulo, M, Riva, A, Ciancio, G, Zehender, G, Taliani, G, Meroni, L, Sollima, S, Sarzi-Puttini, P, Galli, M, Sebastiani, M, Milazzo, L, Atzeni, F, Vacchi, C, Manfredi, A, Quartuccio, L, Scire, C, Gaeta, Gb, Lapadula, G, Armignacco, O, Tavio, M, D'Angelo, S, Meroni, P, Bazzichi, L, Grassi, W, Mathieu, A, Mastroianni, C, Sagnelli, E, Santantonio, T, Uberti Foppa, C, Puoti, M, Sarmati, L, Airo, P, Epis, Om, Scrivo, R, Gargiulo, M, Riva, A, Ciancio, G, Zehender, G, Taliani, G, Meroni, L, Sollima, S, Sarzi-Puttini, P, and Galli, M

Published
2019

21. Italian consensus guidelines for the management of hepatitis B virus infections in patients with rheumatoid arthritis [Prise en charge de l'infection par le virus de l'hépatite B chez les patients atteints de polyarthrite rhumatoïde: conférence de consensus italienne]

Author

Sebastiani, M, Atzeni, F, Milazzo, L, Quartuccio, L, Scire', C, Gaeta, G, Lapadula, G, Armignacco, O, Tavio, M, Olivieri, I, Meroni, P, Bazzichi, L, Grassi, W, Mathieu, A, Mastroianni, C, Sagnelli, E, Santantonio, T, Uberti Foppa, C, Puoti, M, Sarmati, L, Airo, P, Epis, O, Scrivo, R, Gargiulo, M, Riva, A, Manfredi, A, Ciancio, G, Zehender, G, Taliani, G, Meroni, L, Sollima, S, Sarzi-Puttini, P, Galli, M, Sebastiani M., Atzeni F., Milazzo L., Quartuccio L., Scire' C., Gaeta G. B., Lapadula G., Armignacco O., Tavio M., Olivieri I., Meroni P., Bazzichi L., Grassi W., Mathieu A., Mastroianni C., Sagnelli E., Santantonio T., Uberti Foppa C., Puoti M., Sarmati L., Airo P., Epis O. M., Scrivo R., Gargiulo M., Riva A., Manfredi A., Ciancio G., Zehender G., Taliani G., Meroni L., Sollima S., Sarzi-Puttini P., Galli M., Sebastiani, M, Atzeni, F, Milazzo, L, Quartuccio, L, Scire', C, Gaeta, G, Lapadula, G, Armignacco, O, Tavio, M, Olivieri, I, Meroni, P, Bazzichi, L, Grassi, W, Mathieu, A, Mastroianni, C, Sagnelli, E, Santantonio, T, Uberti Foppa, C, Puoti, M, Sarmati, L, Airo, P, Epis, O, Scrivo, R, Gargiulo, M, Riva, A, Manfredi, A, Ciancio, G, Zehender, G, Taliani, G, Meroni, L, Sollima, S, Sarzi-Puttini, P, Galli, M, Sebastiani M., Atzeni F., Milazzo L., Quartuccio L., Scire' C., Gaeta G. B., Lapadula G., Armignacco O., Tavio M., Olivieri I., Meroni P., Bazzichi L., Grassi W., Mathieu A., Mastroianni C., Sagnelli E., Santantonio T., Uberti Foppa C., Puoti M., Sarmati L., Airo P., Epis O. M., Scrivo R., Gargiulo M., Riva A., Manfredi A., Ciancio G., Zehender G., Taliani G., Meroni L., Sollima S., Sarzi-Puttini P., and Galli M.

Published
2018

28. Evolving treatment implementation among HIV- infected pregnant women and their partners: Results from a national surveillance study in Italy, 2001-2015

Author

Floridia, M., Frisina, V. b., Ravizza, M., Marconi, A. M., Pinnetti, C., Cetin, I., Sansone, M., Molinari, A., Cervi, F., Meloni, A., Luzi, K., Masuelli, G., Tamburrini, E., Ensoli, B., Moroni, M., Lazzarin, A., Sagnelli, E., Antinori, A., Carosi, G., Marcotullio, S., Mazzotta, F., Vella, S., Ammassari, A., Antonucci, G., Andreoni, M., Angarano, G., Armignacco, O., Babudieri, S., Baldelli, F., Bini, T., Bonfanti, Bonora, P., Borderi, S., Bruno, M., Bucciardini, R., Castagna, R, Cattelan, A., Cauda, A. M., Cerioli, R., Chirianni, A., Cingolani, A., Cinque, A., D'Arminio, Monforte, Carli, De, Luca, De, Perri, Di, Pietro, Di, Hamad, El, Errico, I., Ferrazzi, M., Gabrielli, E., Galli, E., Giaquinto, M., Girardi, C., Gori, E., Grossi, A., Guaraldi, P., Liuzzi, G., Caputo, Lo, Maggiolo, S., Malena, F., Maserati, M., Mastroianni, R., Matteelli, C., Morrone, A., Murri, A., Mussini, R., Nasta, C., Oldrini, P., Oleari, M., Orlando, F., Palù, G., Pempinello, G., Perno, R., Prestileo, C., Pompa, T., Puoti, M. G., Puro, M., Rancilio, V., Rasi, L., Rizzardini, G., Savasi, G., Signorini, V. M., Sighinolfi, L., Stagnitta, L., Starace, M., Starnini, F., Sterrantino, G., Suter, G., Tambussi, F., Tavio, G., Torti, M., Tozzi, C., Trotta, V., Vaccher, M. P., Viganò, E., Visintini, A., Vullo, R., Zuccotti, V., Dell'Isola, G. V., Manfredini, S., Parisi, V., Pezzoli, S., M. C., Floridia, M, Frisina, V, Ravizza, M, Marconi, A, Pinnetti, C, Cetin, I, Sansone, M, Molinari, A, Cervi, F, Meloni, A, Luzi, K, Masuelli, G, Tamburrini, E, Ensoli, B, Moroni, M, Lazzarin, A, Sagnelli, E, Antinori, A, Carosi, G, Marcotullio, S, Mazzotta, F, Vella, S, Ammassari, A, Antonucci, G, Andreoni, M, Angarano, G, Armignacco, O, Babudieri, S, Baldelli, F, Bini, T, Bonfanti, P, Bonora, S, Borderi, M, Bruno, R, Bucciardini, R, Castagna, A, Cattelan, A, Cauda, R, Cerioli, A, Chirianni, A, Cingolani, A, Cinque, P, d'Arminio Monforte, A, De Carli, G, De Luca, A, Di Perri, G, Di Pietro, M, El Hamad, I, Errico, M, Ferrazzi, E, Gabrielli, E, Galli, M, Giaquinto, C, Girardi, E, Gori, A, Grossi, P, Guaraldi, G, Liuzzi, G, Lo Caputo, S, Maggiolo, F, Malena, M, Maserati, R, Mastroianni, C, Matteelli, A, Morrone, A, Murri, R, Mussini, C, Nasta, P, Oldrini, M, Oleari, F, Orlando, G, Palu, G, Pempinello, R, Perno, C, Prestileo, T, Pompa, M, Puoti, M, Puro, V, Rancilio, L, Rasi, G, Rizzardini, G, Savasi, V, Signorini, L, Sighinolfi, L, Stagnitta, M, Starace, F, Starnini, G, Sterrantino, G, Suter, F, Tambussi, G, Tavio, M, Torti, C, Tozzi, V, Trotta, M, Vaccher, E, Vigano, A, Visintini, R, Vullo, V, Zuccotti, G, Dell'Isola, S, Manfredini, V, Parisi, S, Pezzoli, M, Zona, S, Floridia, M., Frisina, V., Ravizza, M., Marconi, A. M., Pinnetti, C., Cetin, I., Sansone, M., Molinari, A., Cervi, F., Meloni, A., Luzi, K., Masuelli, G., Tamburrini, E., Ensoli, B., Moroni, M., Lazzarin, A., Sagnelli, E., Antinori, A., Carosi, G., Marcotullio, S., Mazzotta, F., Vella, S., Ammassari, A., Antonucci, G., Andreoni, M., Angarano, G., Armignacco, O., Babudieri, S., Baldelli, F., Bini, T., Bonfanti, P., Bonora, S., Borderi, M., Bruno, R., Bucciardini, R., Castagna, A., Cattelan, A. M., Cauda, R., Cerioli, A., Chirianni, A., Cingolani, A., Cinque, P., d'Arminio Monforte, A., De Carli, G., De Luca, A., Di Perri, G., Di Pietro, M., El Hamad, I., Errico, M., Ferrazzi, E., Gabrielli, E., Galli, M., Giaquinto, C., Girardi, E., Gori, A., Grossi, P., Guaraldi, G., Liuzzi, G., Lo Caputo, S., Maggiolo, F., Malena, M., Maserati, R., Mastroianni, C., Matteelli, A., Morrone, A., Murri, R., Mussini, C., Nasta, P., Oldrini, M., Oleari, F., Orlando, G., Palu, G., Pempinello, R., Perno, C. -F., Prestileo, T., Pompa, M. G., Puoti, M., Puro, V., Rancilio, L., Rasi, G., Rizzardini, G., Savasi, V. M., Signorini, L., Sighinolfi, L., Stagnitta, M., Starace, F., Starnini, G., Sterrantino, G., Suter, F., Tambussi, G., Tavio, M., Torti, C., Tozzi, V., Trotta, M. P., Vaccher, E., Vigano, A., Visintini, R., Vullo, V., Zuccotti, G. V., Dell'Isola, S., Manfredini, V., Parisi, S., Pezzoli, M. C., and Zona, S.

Subjects
0301 basic medicine, Male, Infectious Disease Transmission, HIV Infections, Pre-Exposure Prophylaxi, Miscarriage, Cohort Studies, Pre-exposure prophylaxis, 0302 clinical medicine, Pregnancy, Prevalence, Medicine, Vertical, HIV Infection, 030212 general & internal medicine, Pregnancy Complications, Infectious, Treatment implementation, Obstetrics, Health Policy, Medicine (all), Infectious, Pregnancy Outcome, Articles, 3. Good health, Sexual Partner, Sexual Partners, Italy, Serodiscordant, Chemoprophylaxis, Female, Live birth, Adolescent, Adult, Anti-HIV Agents, Fertilization, Humans, Infectious Disease Transmission, Vertical, Pre-Exposure Prophylaxis, Cohort study, Human, medicine.medical_specialty, 03 medical and health sciences, Environmental health, business.industry, Public Health, Environmental and Occupational Health, Anti-HIV Agent, medicine.disease, 030112 virology, Pregnancy Complications, Pregnancy Complications, Infectiou, Cohort Studie, business
Abstract

Background The current global and national indications for antiretroviral treatment (ART, usually triple combination therapy) in adolescent and adults, including pregnant women, recommend early ART before immunologic decline, pre-exposure chemoprophylaxis (PrEP), and treatment of HIV-negative partners in serodiscordant couples. There is limited information on the implementation of these recommendations among pregnant women with HIV and their partners. Methods The present analysis was performed in 2016, using data from clinical records of pregnant women with HIV, followed between 2001 and 2015 at hospital or university clinics within a large, nationally representative Italian cohort study. The study period was divided in three intervals of five years each (2001-2005, 2006-2010, 2011-2015), and the analysis evaluated temporal trends in rates of HIV diagnosis in pregnancy, maternal antiretroviral treatment at conception, prevalence of HIV infection among partners of pregnant women with HIV, and proportion of seronegative and seropositive male partners receiving antiretroviral treatment. Results The analysis included 2755 pregnancies in women with HIV. During the three time intervals considered the rate of HIV diagnosis in pregnancy (overall 23.3%), and the distribution of HIV status among male partners (overall 48.7% HIV- negative, 28.6% HIV-positive and 22.8% unknown) remained substantially unchanged. Significant increases were observed in the proportion of women with HIV diagnosed before pregnancy who were on antiretroviral treatment at conception (from 62.0% in 2001-2005 to 81.3% in 2011-2015, P < 0.001), and in the proportion of HIV-positive partners on antiretroviral treatment (from 73.3% in 2001-2005 to 95.8% in 2011-2015, P = 0.002). Antiretroviral treatment was administered in 99.1% of the pregnancies that did not end early because of miscarriage, termination, or intrauterine death, and in 75.3% of those not ending in a live birth. No implementation of antiretroviral treatment was introduced among male HIV-negative partners. Conclusions The results suggest good implementation of antiretroviral treatment among HIV-positive women and their HIV-positive partners, but no implementation, even in recent years, of Pre-Exposure Prophylaxis (PrEP) among uninfected male partners. Further studies should assess the determinants of this occurrence and clarify the attitudes and the potential barriers to PrEP use.

Published
2017

31. Hepatitis C late relapse in patients with directly acting antiviral-related sustained virological response at week 12

Author

Pisaturo M, Minichini C, Starace M, Caroprese M, Macera M, Brancaccio G, De Pascalis S, Santonicola A, Galeota Lanza A, Zampino R, Cotticelli G, Sagnelli E, Gaeta GB, Coppola N, Pisaturo, M, Minichini, C, Starace, M, Caroprese, M, Macera, M, Brancaccio, G, De Pascalis, S, Santonicola, A, Galeota Lanza, A, Zampino, R, Cotticelli, G, Sagnelli, E, Gaeta, Gb, and Coppola, N

Published
2018

32. VIROLOGICAL PATTERNS OF HCV PATIENTS WITH FAILURE TO INTERFERON-FREE REGIMENS

Author

Starace M, Minichini C, De Pascalis S, Macera M, Occhiello L, Messina V, Sangiovanni V, Adinolfi LE, Claar E, Precone D, Stornaiuolo G, Stanzione M, Ascione T, Caroprese M, Zampino R, Parrilli G, Gentile I, Brancaccio G, Iovinella V, Martini S, Masarone M, Fontanella L, Masiello A, Sagnelli E, Punzi R, Salomone Megna A, Santoro R, Gaeta GB, Coppola N., Zampino R. Parrilli G, Masarone M., Starace, Mario, Minichini, Carmine, De Pascalis, Stefania, Macera, Margherita, Occhiello, Laura, Messina, Vincenzo, Sangiovanni, Vincenzo, Adinolfi, Luigi E, Claar, Ernesto, Precone, Davide, Stornaiuolo, Gianfranca, Stanzione, Maria, Ascione, Tiziana, Caroprese, Mara, Zampino, Rosa, Parrilli, Gianpaolo, Gentile, Ivan, Brancaccio, Giuseppina, Iovinella, Vincenzo, Martini, Salvatore, Masarone, Mario, Fontanella, Luca, Masiello, Addolorata, Sagnelli, Evangelista, Punzi, Rodolfo, Salomone Megna, Angelo, Santoro, Renato, Gaeta, Giovanni B, Coppola, Nicola, Starace, M, Minichini, C, De Pascalis, S, Macera, M, Occhiello, L, Messina, V, Sangiovanni, V, Adinolfi, Le, Claar, E, Precone, D, Stornaiuolo, G, Stanzione, M, Ascione, T, Caroprese, M, Zampino, R, Parrilli, G, Gentile, I, Brancaccio, G, Iovinella, V, Martini, S, Masarone, M, Fontanella, L, Masiello, A, Sagnelli, E, Punzi, R, Salomone Megna, A, Santoro, R, Gaeta, Gb, Coppola, N., Zampino R., Parrilli G, and Masarone, M.

Subjects
0301 basic medicine, Simeprevir, Male, Hepacivirus, Viral Nonstructural Proteins, Hospitals, University, 0302 clinical medicine, Genotype, antiviral therapy, Prevalence, Treatment Failure, Sanger sequencing, Aged, 80 and over, education.field_of_study, virus diseases, Middle Aged, chronic HCV hepatitis, Infectious Diseases, Italy, symbols, DAA failure, 030211 gastroenterology & hepatology, Female, Adult, RASs, medicine.medical_specialty, Population, Mutation, Missense, Antiviral Agents, 03 medical and health sciences, symbols.namesake, Virology, Internal medicine, Drug Resistance, Viral, medicine, Humans, In patient, NS5A, education, DAAs, DAA, Aged, business.industry, Interferon free, Genetic Variation, Sequence Analysis, DNA, Hepatitis C, Chronic, digestive system diseases, Regimen, 030104 developmental biology, Amino Acid Substitution, business, RAS
Abstract

The study characterized the virological patterns and the resistance-associated substitutions (RASs) in patients with failure to IFN-free regimens enrolled in the real-life setting. All 87 consecutive HCV patients with failed IFN-free regimens, observed at the laboratory of the University of Campania, were enrolled. All patients had been treated with DAA regimens according to the HCV genotype, international guidelines, and local availability. Sanger sequencing of NS3, NS5A, and NS5B regions was performed at failure by home-made protocols. Of the 87 patients enrolled, 13 (14.9%) showed a misclassified HCV genotype, probably causing DAA failure, 16 had been treated with a sub-optimal DAA regimen, 19 with a simeprevir-based regimen and 39 with an optimal DAA regimen. A major RAS was identified more frequently in the simeprevir regimen group (68.4%) and in the optimal regimen group (74.4%) than in the sub-optimal regimen group (56.3%). The prevalence of RASs in NS3 was similar in the three groups (30.8-57.9%), that in NS5A higher in the optimal regimen group (71.8%) than in the sub-optimal regimen group (12.5%, P < 0.0001) and in the simeprevir regimen group (31.6%, P < 0.0005), and that in NS5B low in all groups (0-25%). RASs in two or more HCV regions were more frequently identified in the optimal regimen group (46.6%) than in the simeprevir-based regimen group (31.6%) and sub-optimal regimen group (18.7%). In our real-life population the prevalence of RASs was high, especially in NS3 and NS5A and in those treated with suitable DAA regimens. © 2018 Wiley Periodicals, Inc.

Published
2018

33. Evolving treatment implementation among HIV- infected pregnant women and their partners: Results from a national surveillance study in Italy, 2001-2015

Author

Floridia, M, Frisina, V, Ravizza, M, Marconi, A, Pinnetti, C, Cetin, I, Sansone, M, Molinari, A, Cervi, F, Meloni, A, Luzi, K, Masuelli, G, Tamburrini, E, Ensoli, B, Moroni, M, Lazzarin, A, Sagnelli, E, Antinori, A, Carosi, G, Marcotullio, S, Mazzotta, F, Vella, S, Ammassari, A, Antonucci, G, Andreoni, M, Angarano, G, Armignacco, O, Babudieri, S, Baldelli, F, Bini, T, Bonfanti, P, Bonora, S, Borderi, M, Bruno, R, Bucciardini, R, Castagna, A, Cattelan, A, Cauda, R, Cerioli, A, Chirianni, A, Cingolani, A, Cinque, P, d'Arminio Monforte, A, De Carli, G, De Luca, A, Di Perri, G, Di Pietro, M, El Hamad, I, Errico, M, Ferrazzi, E, Gabrielli, E, Galli, M, Giaquinto, C, Girardi, E, Gori, A, Grossi, P, Guaraldi, G, Liuzzi, G, Lo Caputo, S, Maggiolo, F, Malena, M, Maserati, R, Mastroianni, C, Matteelli, A, Morrone, A, Murri, R, Mussini, C, Nasta, P, Oldrini, M, Oleari, F, Orlando, G, Palu, G, Pempinello, R, Perno, C, Prestileo, T, Pompa, M, Puoti, M, Puro, V, Rancilio, L, Rasi, G, Rizzardini, G, Savasi, V, Signorini, L, Sighinolfi, L, Stagnitta, M, Starace, F, Starnini, G, Sterrantino, G, Suter, F, Tambussi, G, Tavio, M, Torti, C, Tozzi, V, Trotta, M, Vaccher, E, Vigano, A, Visintini, R, Vullo, V, Zuccotti, G, Dell'Isola, S, Manfredini, V, Parisi, S, Pezzoli, M, Zona, S, Floridia M., Frisina V., Ravizza M., Marconi A. M., Pinnetti C., Cetin I., Sansone M., Molinari A., Cervi F., Meloni A., Luzi K., Masuelli G., Tamburrini E., Ensoli B., Moroni M., Lazzarin A., Sagnelli E., Antinori A., Carosi G., Marcotullio S., Mazzotta F., Vella S., Ammassari A., Antonucci G., Andreoni M., Angarano G., Armignacco O., Babudieri S., Baldelli F., Bini T., Bonfanti P., Bonora S., Borderi M., Bruno R., Bucciardini R., Castagna A., Cattelan A. M., Cauda R., Cerioli A., Chirianni A., Cingolani A., Cinque P., d'Arminio Monforte A., De Carli G., De Luca A., Di Perri G., Di Pietro M., El Hamad I., Errico M., Ferrazzi E., Gabrielli E., Galli M., Giaquinto C., Girardi E., Gori A., Grossi P., Guaraldi G., Liuzzi G., Lo Caputo S., Maggiolo F., Malena M., Maserati R., Mastroianni C., Matteelli A., Morrone A., Murri R., Mussini C., Nasta P., Oldrini M., Oleari F., Orlando G., Palu G., Pempinello R., Perno C. -F., Prestileo T., Pompa M. G., Puoti M., Puro V., Rancilio L., Rasi G., Rizzardini G., Savasi V. M., Signorini L., Sighinolfi L., Stagnitta M., Starace F., Starnini G., Sterrantino G., Suter F., Tambussi G., Tavio M., Torti C., Tozzi V., Trotta M. P., Vaccher E., Vigano A., Visintini R., Vullo V., Zuccotti G. V., Dell'Isola S., Manfredini V., Parisi S., Pezzoli M. C., Zona S., Floridia, M, Frisina, V, Ravizza, M, Marconi, A, Pinnetti, C, Cetin, I, Sansone, M, Molinari, A, Cervi, F, Meloni, A, Luzi, K, Masuelli, G, Tamburrini, E, Ensoli, B, Moroni, M, Lazzarin, A, Sagnelli, E, Antinori, A, Carosi, G, Marcotullio, S, Mazzotta, F, Vella, S, Ammassari, A, Antonucci, G, Andreoni, M, Angarano, G, Armignacco, O, Babudieri, S, Baldelli, F, Bini, T, Bonfanti, P, Bonora, S, Borderi, M, Bruno, R, Bucciardini, R, Castagna, A, Cattelan, A, Cauda, R, Cerioli, A, Chirianni, A, Cingolani, A, Cinque, P, d'Arminio Monforte, A, De Carli, G, De Luca, A, Di Perri, G, Di Pietro, M, El Hamad, I, Errico, M, Ferrazzi, E, Gabrielli, E, Galli, M, Giaquinto, C, Girardi, E, Gori, A, Grossi, P, Guaraldi, G, Liuzzi, G, Lo Caputo, S, Maggiolo, F, Malena, M, Maserati, R, Mastroianni, C, Matteelli, A, Morrone, A, Murri, R, Mussini, C, Nasta, P, Oldrini, M, Oleari, F, Orlando, G, Palu, G, Pempinello, R, Perno, C, Prestileo, T, Pompa, M, Puoti, M, Puro, V, Rancilio, L, Rasi, G, Rizzardini, G, Savasi, V, Signorini, L, Sighinolfi, L, Stagnitta, M, Starace, F, Starnini, G, Sterrantino, G, Suter, F, Tambussi, G, Tavio, M, Torti, C, Tozzi, V, Trotta, M, Vaccher, E, Vigano, A, Visintini, R, Vullo, V, Zuccotti, G, Dell'Isola, S, Manfredini, V, Parisi, S, Pezzoli, M, Zona, S, Floridia M., Frisina V., Ravizza M., Marconi A. M., Pinnetti C., Cetin I., Sansone M., Molinari A., Cervi F., Meloni A., Luzi K., Masuelli G., Tamburrini E., Ensoli B., Moroni M., Lazzarin A., Sagnelli E., Antinori A., Carosi G., Marcotullio S., Mazzotta F., Vella S., Ammassari A., Antonucci G., Andreoni M., Angarano G., Armignacco O., Babudieri S., Baldelli F., Bini T., Bonfanti P., Bonora S., Borderi M., Bruno R., Bucciardini R., Castagna A., Cattelan A. M., Cauda R., Cerioli A., Chirianni A., Cingolani A., Cinque P., d'Arminio Monforte A., De Carli G., De Luca A., Di Perri G., Di Pietro M., El Hamad I., Errico M., Ferrazzi E., Gabrielli E., Galli M., Giaquinto C., Girardi E., Gori A., Grossi P., Guaraldi G., Liuzzi G., Lo Caputo S., Maggiolo F., Malena M., Maserati R., Mastroianni C., Matteelli A., Morrone A., Murri R., Mussini C., Nasta P., Oldrini M., Oleari F., Orlando G., Palu G., Pempinello R., Perno C. -F., Prestileo T., Pompa M. G., Puoti M., Puro V., Rancilio L., Rasi G., Rizzardini G., Savasi V. M., Signorini L., Sighinolfi L., Stagnitta M., Starace F., Starnini G., Sterrantino G., Suter F., Tambussi G., Tavio M., Torti C., Tozzi V., Trotta M. P., Vaccher E., Vigano A., Visintini R., Vullo V., Zuccotti G. V., Dell'Isola S., Manfredini V., Parisi S., Pezzoli M. C., and Zona S.

Abstract

Background The current global and national indications for antiretroviral treatment (ART, usually triple combination therapy) in adolescent and adults, including pregnant women, recommend early ART before immunologic decline, pre-exposure chemoprophylaxis (PrEP), and treatment of HIV-negative partners in serodiscordant couples. There is limited information on the implementation of these recommendations among pregnant women with HIV and their partners. Methods The present analysis was performed in 2016, using data from clinical records of pregnant women with HIV, followed between 2001 and 2015 at hospital or university clinics within a large, nationally representative Italian cohort study. The study period was divided in three intervals of five years each (2001-2005, 2006-2010, 2011-2015), and the analysis evaluated temporal trends in rates of HIV diagnosis in pregnancy, maternal antiretroviral treatment at conception, prevalence of HIV infection among partners of pregnant women with HIV, and proportion of seronegative and seropositive male partners receiving antiretroviral treatment. Results The analysis included 2755 pregnancies in women with HIV. During the three time intervals considered the rate of HIV diagnosis in pregnancy (overall 23.3%), and the distribution of HIV status among male partners (overall 48.7% HIV- negative, 28.6% HIV-positive and 22.8% unknown) remained substantially unchanged. Significant increases were observed in the proportion of women with HIV diagnosed before pregnancy who were on antiretroviral treatment at conception (from 62.0% in 2001-2005 to 81.3% in 2011-2015, P < 0.001), and in the proportion of HIV-positive partners on antiretroviral treatment (from 73.3% in 2001-2005 to 95.8% in 2011-2015, P = 0.002). Antiretroviral treatment was administered in 99.1% of the pregnancies that did not end early because of miscarriage, termination, or intrauterine death, and in 75.3% of those not ending in a live birth. No implementation of antir

Published
2017

34. Italian consensus Guidelines for the management of hepatitis B virus infections in patients with rheumatoid arthritis

Author

Sebastiani, M, Atzeni, F, Milazzo, L, Quartuccio, L, Scirè, C, Gaeta, G, Lapadula, G, Armignacco, O, Tavio, M, Olivieri, I, Meroni, P, Bazzichi, L, Grassi, W, Mathieu, A, Mastroianni, C, Sagnelli, E, Santantonio, T, Uberti Foppa, C, Puoti, M, Sarmati, L, Airò, P, Epis, O, Scrivo, R, Gargiulo, M, Riva, A, Manfredi, A, Ciancio, G, Zehender, G, Taliani, G, Meroni, L, Sollima, S, Sarzi-Puttini, P, Galli, M, Sebastiani M, Atzeni F, Milazzo L, Quartuccio L, Scirè C, Gaeta GB, Lapadula G, Armignacco O, Tavio M, Olivieri I, Meroni P, Bazzichi L, Grassi W, Mathieu A, Mastroianni C, Sagnelli E, Santantonio T, Uberti Foppa C, Puoti M, Sarmati L, Airò P, Epis OM, Scrivo R, Gargiulo M, Riva A, Manfredi A, Ciancio G, Zehender G, Taliani G, Meroni L, Sollima S, Sarzi-Puttini P, Galli M., Sebastiani, M, Atzeni, F, Milazzo, L, Quartuccio, L, Scirè, C, Gaeta, G, Lapadula, G, Armignacco, O, Tavio, M, Olivieri, I, Meroni, P, Bazzichi, L, Grassi, W, Mathieu, A, Mastroianni, C, Sagnelli, E, Santantonio, T, Uberti Foppa, C, Puoti, M, Sarmati, L, Airò, P, Epis, O, Scrivo, R, Gargiulo, M, Riva, A, Manfredi, A, Ciancio, G, Zehender, G, Taliani, G, Meroni, L, Sollima, S, Sarzi-Puttini, P, Galli, M, Sebastiani M, Atzeni F, Milazzo L, Quartuccio L, Scirè C, Gaeta GB, Lapadula G, Armignacco O, Tavio M, Olivieri I, Meroni P, Bazzichi L, Grassi W, Mathieu A, Mastroianni C, Sagnelli E, Santantonio T, Uberti Foppa C, Puoti M, Sarmati L, Airò P, Epis OM, Scrivo R, Gargiulo M, Riva A, Manfredi A, Ciancio G, Zehender G, Taliani G, Meroni L, Sollima S, Sarzi-Puttini P, and Galli M.

Abstract

Objectives Hepatitis B (HBV) infection, which is prevalent worldwide, is also frequently seen in patients with rheumatoid arthritis (RA). The Italian Society of Rheumatology (SIR) and the Italian Society of Infectious and Tropical Diseases (SIMIT) endorsed a national consensus process to review the available evidence on HBV management in RA patients and to produce practical, hospital-wide recommendations. Methods The consensus panel consisted of infectious disease consultants, rheumatologists and epidemiologists and used the criteria of the Oxford Center for Evidence-based Medicine to assess the quality of the evidence and the strength of their recommendations. Results A core-set of statements has been developed to help clinicians in the management of patients with RA and HBV infection. Vaccination and prophylaxis of RA patients treated with biological drugs have been also discussed. Conclusions HBV infection is not rare in clinical practice; a screening for HBV in all patients with early arthritis is not universally accepted, while it is considered mandatory before starting any immunosuppressive or hepatotoxic treatment. In fact, a specific risk, associated with the use of biologic treatments, exists for patients with HBV infection, although longitudinal studies of viral reactivation are generally reassuring. RA patients with HBV infection should be referred to the hepatologist and correctly classified into active or inactive carriers. Patients with active hepatitis B should undergo antiviral treatment before starting immunosuppressive treatments. Occult HBV carriers should be monitored or receive prophylaxis on the basis of the risk of reactivation associated with the administered treatment.

Published
2017

38. Clinical, epidemiological and virological features of acute hepatitis B in Italy

Author

Zuccaro O, Romanò L, Mele A, Mariano A, Clementi M, Tosti ME, Taliani G, Galli C, Zanetti AR, Spada E, Raise E, Eseme FE, Maio G, Rummo G, Maio P, Di Giuli C, Bellissima P, Bonfante S, Chiriacò P, Cacopardo B, Blanc P, Palattella S, Santantonio T, Guastadisegni A, Amoroso P, Fabris P, Giordani MT, Vullo V, Giuberti T, Schivazzappa S, Trezzi M, Biagetti C, Pocaterra D, Sagnelli E, Messina V, Antonucci G, Spallanzani L, Vairo F, Marinelli M, Paladini S, Tagliacarne C., VERUCCHI, GABRIELLA, Zuccaro O, Romanò L, Mele A, Mariano A, Clementi M, Tosti ME, Taliani G, Galli C, Zanetti AR, Spada E, Raise E, Eseme FE, Maio G, Rummo G, Maio P, Di Giuli C, Bellissima P, Bonfante S, Chiriacò P, Cacopardo B, Blanc P, Palattella S, Santantonio T, Guastadisegni A, Amoroso P, Fabris P, Giordani MT, Vullo V, Giuberti T, Schivazzappa S, Trezzi M, Verucchi G, Biagetti C, Pocaterra D, Sagnelli E, Messina V, Antonucci G, Spallanzani L, Vairo F, Marinelli M, Paladini S, Tagliacarne C, Zuccaro, O., Romano, L., Mele, A., Mariano, A., Clementi, M., Tosti, M. E., Taliani, G., Galli, C., Zanetti, A. R., and Spada, E.

Subjects
Adult, Male, Microbiology (medical), Hepatitis B virus, medicine.medical_specialty, Adolescent, Genotype, Epidemiology, Genotypes, Gene mutation, medicine.disease_cause, Cohort Studies, Young Adult, Basal (phylogenetics), 80 and over, medicine, Humans, Hepatitis B Vaccines, Prospective Studies, Acute infection, Hepatitis B, Mutations, Risk factors, Aged, Acute Disease, Aged, 80 and over, Female, Follow-Up Studies, Hepatitis B Core Antigens, Italy, Middle Aged, Infectious Diseases, business.industry, Promoter, General Medicine, medicine.disease, Virology, Mutation, Immunology, Acute hepatitis B, business
Abstract

Purpose: To evaluate the association of hepatitis B virus (HBV) genotypes, basal core promoter (BCP)/precore (PC) and S gene mutations with the clinical-epidemiological characteristics of acute hepatitis B (AHB) in Italy. Methods: During July 2005–January 2007, 103 symptomatic AHB patients were enrolled and prospectively followed up at 15 national hospitals. HBV genotypes, BCP/PC and S gene variants were determined by nested-PCR and direct sequence analysis. Results: Genotype D, A and F were detected in 49, 45 and 6% of patients, respectively. BCP, PC, and BCP plus PC variants were found in 3.1, 11.3 and 7.2% of patients, respectively. At enrollment, 68.3% of patients were hepatitis B e antigen (HBeAg)-positive and 31.7% HBeAg-negative. BCP/PC mutations were more common in HBeAg-negative than in HBeAg-positive patients (p&nbsp

Published
2015

44. An update on the treatment options for HBV/HCV coinfection

Author

Sagnelli E., Sagnelli C., Macera M., Pisaturo M., Coppola N., Sagnelli, E., Sagnelli, C., Macera, M., Pisaturo, M., and Coppola, N.

Subjects
Antiviral Agent, Guanine, Anti-HIV Agents, Coinfection, HBV/HCV treatment, HBV/HCV epidemiology, virus diseases, Anti-HIV Agent, HIV Infections, Antiviral Agents, Hepatitis C, digestive system diseases, HBV/HCV coinfection, HBV/HCV interaction, Humans, HIV Infection, Tenofovir, Human
Abstract

Introduction: Despite the reciprocal inhibition exerted by HBV and HCV genomes, dual HBV/HCV infection is associated with more severe forms of liver disease and warrant effective treatment. Areas covered: A careful evaluation of disease progression to establish the predominance of one virus over another, concomitant HIV infection and comorbidities is essential to make the best therapy choices. In most virological conditions interferon (IFN)-based treatment has been replaced by a combination of different classes of second generation directly acting antivirals (DAAs), which offer better tolerability and HCV eradication in 95% of cases. Tenofovir or entecavir should be part of treatment for patients with active HBV production, for those coinfected with HIV and for those with cirrhosis. Expert opinion: DAAs have been successfully used to eradicate HCV infection in recent years, but the high cost may limit their use particularly in developing countries. Entecavir and tenofovir have been demonstrated to be effective for long-term inhibition of HBV replication. Careful monitoring of serum ALT and markers of HBV and HCV replication before and during treatment is essential for an early diagnosis and treatment of virus reactivation.

Published
2017

45. Interferon-Free Regimens in Hepatitis B Surface Antigen/Anti-Hepatitis C Virus Positive Patients: The Need to Control Hepatitis B Virus Replication to Avoid Hepatitis B Virus Reactivation

Author

Macera M, Stanzione M, Messina V, D'Adamo G, Sangiovanni V, Mioglioresi L, Fontanella L, De Pascalis S, Stornaiuolo G, Galeota Lanza A, Ascione T, Sagnelli E, Gentile I, Piai G, Gaeta GB, Coppola N., Macera, M, Stanzione, M, Messina, V, D'Adamo, G, Sangiovanni, V, Mioglioresi, L, Fontanella, L, De Pascalis, S, Stornaiuolo, G, Galeota Lanza, A, Ascione, T, Sagnelli, E, Gentile, I, Piai, G, Gaeta, Gb, and Coppola, N.

Published
2017

48. The CB2-63 RR variant is an independent predictor of severe liver necroinflammation in chronic hepatitis B

Author

Coppola N, Zampino R, Bellini G, Stanzione M, Capoluongo N, Marrone A, Macera M, Pasquale G, Boemio A, Maione S, Adinolfi LE, Miraglia Del Giudice E, Sagnelli E, Rossi F., Coppola N, Zampino R, Bellini G, Stanzione M, Capoluongo N, Marrone A, Macera M, Pasquale G, Boemio A, Maione S, Adinolfi LE, Miraglia Del Giudice E, Sagnelli E, Rossi F., Coppola, N, Zampino, R, Bellini, G, Stanzione, M, Capoluongo, N, Marrone, A, Macera, M, Pasquale, G, Boemio, A, Maione, S, Adinolfi, Le, Miraglia Del Giudice, E, Sagnelli, E, and Rossi, F.

Published
2015

49. The TM6SFZ 8167K variant is an independent predictor of severe liver steatosis in chronic hepatitis C

Author

Coppola N, Zampino R, Cirillo G, Stanzione M, Macera M, Boemio A, Grandone A, Pisaturo M, Marrone A, Adinolfi LE, Miraglia Del Giudice E, Sagnelli E., Coppola N, Zampino R, Cirillo G, Stanzione M, Macera M, Boemio A, Grandone A, Pisaturo M, Marrone A, Adinolfi LE, Miraglia Del Giudice E, Sagnelli E, Coppola, N, Zampino, R, Cirillo, G, Stanzione, M, Macera, M, Boemio, A, Grandone, A, Pisaturo, M, Marrone, A, Adinolfi, Le, Miraglia Del Giudice, E, and Sagnelli, E.

Published
2015

50. PNPLA3 I148M variant is associated with liver steatosis and fat distribution in chronic hepatitis B

Author

Zampino R, Coppola N, Cirillo G, Boemio A, Grandone A, Stanzione M, Capoluongo N, Marrone A, Macera M, Sagnelli E, Adinolfi LE, Miraglia Del Giudice E., Zampino R, Coppola N, Cirillo G, Boemio A, Grandone A, Stanzione M, Capoluongo N, Marrone A, Macera M , Sagnelli E, Adinolfi LE, Miraglia Del Giudice E, Zampino, R, Coppola, N, Cirillo, G, Boemio, A, Grandone, A, Stanzione, M, Capoluongo, N, Marrone, A, Macera, M, Sagnelli, E, Adinolfi, Le, and Miraglia Del Giudice, E.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results